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Purpose: To investigate the efficacy of dorzolamide 1% (bid or tid) or brinzolamide 1% bid on 
24-hour intraocular pressure (IOP) control as well as patients’ preference for either drug when 
added in combination with latanoprost against glaucoma (IOP, 18 mmHg).
Methods: In this randomized crossover study patients were assigned to receive latanoprost plus 
either dorzolamide or brinzolamide for four weeks. Thereafter, patients underwent 24-hour IOP 
monitoring while continuing to receive dorzolamide (for two successive days/nights: at first 
bid then tid) or brinzolamide bid (once overnight). They were then switched over to receive the 
other test medication for a further four weeks and subsequently reexamined for 24-hour IOP. 
A questionnaire survey on treatment satisfaction was performed.
Results: In 20 patients dorzolamide bid or tid or brinzolamide bid exerted significant (p  0.001) 
reductions of IOP from baseline at all time-points over 24 hours; no difference was detected 
among the treatment regimens. Significantly (p  0.05) more patients preferred dorzolamide 
(n = 9) over brinzolamide (n = 2), whereas nine patients gave a neutral answer.
Conclusion: Dorzolamide bid or tid and brinzolamide bid when combined with latanoprost 
therapy elicited significant IOP reduction for 24 hours. It is rational to consider patients’ prefer-
ence of therapeutic regimen especially long-term users such as those with glaucoma.
Keywords: glaucoma, brinzolamide, dorzolamide, latanoprost combination therapy, 24-hour 
intraocular pressure (IOP), questionnaire survey
Introduction
In the management of glaucoma, reduction of intraocular pressure (IOP) is the best 
and only evidence-based treatment modality; pharmacologic as well as surgical 
interventions aimed at reducing IOP may successfully slow the progression of struc-
tural damage and visual field loss in patients with the disease.1–4 Both the Advanced 
Glaucoma Intervention Study3 and Collaborative Initial Glaucoma Treatment Study4 
have shown that IOP reduction should be achieved more aggressively than previously 
thought.
According to the Guidelines on Glaucoma Management in Japan,5 when 
pharmacologic IOP control is insufficient the first-line drug should be switched or 
combined with other medications. Accordingly, many glaucoma patients require 
polypharmacy for adequate IOP control during the life-long course of the disease.6,7 For 
this purpose, significant advances in the development of topical glaucoma medications 
have been achieved.8–10 In recent years, prostaglandin analogs have gained popularity 
as first-line drugs for monotherapy; latanoprost for example effectively reduces IOP 
by increasing aqueous flow through the uveoscleral pathway.11–14 For combination Clinical Ophthalmology 2009:3 396
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therapy with a prostaglandin analog, add-on β-blocker has 
been extensively used and is probably the most common 
combination.15,16 Recently, however, the combined approach 
with latanoprost plus a topical carbonic anhydrase inhibitor 
(CAI) such as dorzolamide or brinzolamide has been dem-
onstrated to lower IOP at least as effectively as that with 
additional β-blocker.17–19 This option of latanoprost plus CAI 
may also confer not only better nighttime IOP reduction than 
β-blocker,20 but also excellent systemic safety profiles.9,19
Although thrice-daily dosing of dorzolamide is officially 
approved in Japan, there is little information comparing the 
IOP-lowering efficacy of this dosing regimen versus that 
of twice-daily medication in Japanese patients. The present 
randomized, prospective study was designed to evaluate 
24-hour control of IOP using dorzolamide 1% bid or tid 
in comparison with the standard CAI treatment in Japan, 
brinzolamide 1% bid, given in combination with latanoprost 
in Japanese patients with glaucoma. Also assessed was the 
patients’ preference for either drug.
Patients and methods
Patients
Male and female glaucoma patients aged 20 years whose 
IOP as ascertained by applanation tonometry (duplicate mea-
surement) was 18 mmHg despite receving monotherapy 
with latanoprost 0.005% once daily for 4 weeks were 
enrolled. Inclusion criteria were primary open-angle glau-
coma (POAG) defined as glaucomatous optic neuropathy 
with repeatable reliable visual field defect demonstrated 
by automated visual field perimetry, ocular hypertension 
(OH) defined as IOP 21 mmHg without visual field 
loss, or post-laser iridotomy (LI) angle-closure glaucoma 
(ACG) defined as gonioscopically occludable angles with 
peripheral anterior synechia (PAS) formation and coexist-
ing glaucomatous neuropathy and visual field loss. Patients 
with history of chronic or recurrent inflammatory eye dis-
ease, ocular trauma, or ocular infection within the past three 
months, corneal abnormality preventing reliable applana-
tion tonometry, those undergoing intraocular surgery or 
currently using any ophthalmic, dermatologic, or systemic 
corticosteroid, oral CAIs, or sulfonamide drugs, and those 
with history of severe hypersensitivity to oral CAIs were 
excluded.
This study was approved and authorized by the Ethics 
Committee of the University of Ryukyus Faculty of Medi-
cine and conducted according to the tenets of the Declaration 
of Helsinki. Written informed consent was obtained from all 
patients prior to study commencement.
Methods
Eligible patients were randomized by two-group crossover 
method to receive either dorzolamide 1% or brinzolamide 
1% (the available formulations in Japan) eye drops twice 
daily (at 09:00 and 21:00) in combination with latano-
prost (given once daily at 21:00) for 4 weeks. At the end 
of four weeks, they were hospitalized as follows. In the 
brinzolamide group, patients continued to receive the 
same combination therapy while their IOP was measured 
by physician specializing in glaucoma using Goldmann 
applanation tonometer every three hours from 09:00 till 
24:00 and at 06:00 and 9:00 the next day. Whereas, in 
the dorzolamide group the patients underwent the same 
24-hour IOP observation as in the brinzolamide group on 
two consecutive days: at first while continuing to receive 
dorzolamide twice daily then over the next 24 hours while 
receiving dorzolamide thrice daily (given at 09:00, 15:00, 
and 21:00). The patients in the two drug treatment groups 
were then crossed over to receive the other test medication 
for another four weeks followed by measurement of 24-hour 
IOP as before.
IOP was analyzed in one eye/patient. If both eyes were 
eligible for inclusion that with higher IOP was selected as 
the study eye; when IOP was the same in both eyes the right 
eye was selected. IOP measurements were conducted in 
duplicate at each time point, with the higher measurement 
adopted and verified by the investigators.
All patients underwent thorough ophthalmic evaluations 
before and at each visit during the study. Subjective 
ocular discomfort and adverse events and their duration 
after instillation of eye drops were investigated by patient 
interviews. Patients who complained of irritation and/or 
blurred vision at least once during the experimental period 
were regarded as having ocular discomfort. At the end of the 
study, the patients were asked to express any preference for 
dorzolamide or brinzolamide.
statistical analysis
Data are expressed as mean ± standard deviation (SD). 
Intragroup differences between baseline and on-treatment 
IOP were analyzed by multiple comparison method after 
repeated measures analysis of variance (ANOVA). Percent 
IOP reduction in daytime and nighttime and area under the 
curve (AUC) of 24-hour IOP were compared among treatment 
groups by ANOVA with ad hoc multiple comparison method. 
AUC was squared in each trapezoid. Patient survey results were 
compared by Fisher’s exact test. All statistical tests were per-
formed with α = 0.05 at two-tailed and with 80% power (1–β). Clinical Ophthalmology 2009:3 397
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P-values  0.05 were considered statistically significant. 
All statistical analyses were performed using STATISTICA 
version 06J (StatSoft Japan Inc, Tokyo, Japan).
Results
This study involved 20 Japanese patients (M/F, 11/9; mean 
age, 65.7 ± 10.2 years). Eleven patients had POAG, three 
OH, and six ACG. All ACG patients had been treated with 
LI  3 months before enrolment in this study. Although all 
20 patients in the dorzolamide bid and brinzolamide bid groups 
underwent 24-hour assessment of IOP, only 17 patients did so in 
the dorzolamide tid group; the reason for dropping out was per-
sonal choice (not because of side effects) in all three cases.
Mean baseline IOP was 20.0 ± 1.4 mmHg. After four 
weeks of treatment and during hospital stay, mean IOP 
values on both drugs in combination with latanoprost 
were significantly (p  0.001) reduced from baseline at 
all time-points throughout the 24-hour period as shown in 
Table 1 and Figure 1.
Percent reduction of IOP from baseline on dorzolamide 
bid and tid and brinzolamide bid was 17.3 ± 10.0%, 
21.0 ± 9.4%, and 17.8 ± 8.8%, respectively, during daytime 
and 21.1 ± 9.5%, 20.5 ± 10.2%, and 18.5 ± 11.7%, respectively, 
at night (Table 2 and Figure 2). No significant difference was 
noted among the three groups. AUC of IOP reduction over 
24 hours in the three treatment groups was 385 ± 39, 381 ± 39, 
and 394 ± 47 mmHg⋅hour, respectively.
Ocular discomfort/adverse events during the treatment 
period were mild eye irritation (n = 8), mild foreign body 
sensation (n = 1), and mild blurred vision (n = 3) in patients 
receiving dorzolamide and mild eye irritation (n = 4), 
mild foreign body sensation (n = 2), and blurred vision 
(n = 12; severe in 2 patients and mild in 10 patients) in 
those receiving brinzolamide (Figure 3). According to the 
patients' questionnaire survey conducted at end of study, 
significantly (P  0.05) more patients favored dorzolamide 
1% (n = 9) than brinzolamide 1% (n = 2), whereas nine 
patients did not express any preference for either drug. The 
major reported reasons for preference of dorzolamide over 
brinzolamide were that brinzolamide left white residue on 
eye lashes and caused long-lasting blurred vision including 
severe blurring in two cases.
Discussion
In the present study dorzolamide 1% applied twice or thrice 
daily and brinzolamide 1% twice daily exerted significant 
24-hour IOP-lowering activity when added to latanoprost in 
Japanese patients with POAG, OH, and ACG. The 24-hour 
IOP-lowering efficacy of each CAI as second-line medication 
in combination therapy with latanoprost appeared similar, 
as did that of the twice- and thrice-daily dosing schedules 
of dorzolamide. However, patients’ preference significantly 
favored dorzolamide over brinzolamide mainly because of 
whitish precipitate and blurred vision of long duration asso-
ciated with instillation of the latter eye drops; irritation was 
not a significant factor in this result.
In a previous study looking at IOP reduction, brinzol-
amide 1% exerted equivalent efficacy to dorzolamide 2% 
when added to timolol 0.5% in patients with POAG and OH.21 
Moreover, when added to latanoprost in patients with glaucoma 
and OH, dorzolamide 2% decreased IOP by 3.9 mmHg 
(19.7%).17 Whereas, addition of brinzolamide to latanoprost 
reduced IOP by 5.2 mmHg (24.6%) in patients with POAG 
or OH.18 IOP was maintained without further decrease when 
brinzolamide 1% was substituted for dorzolamide 1% in com-
bination therapy with latanoprost and timolol.22,23 The present 
study demonstrated almost identical effect on IOP reduction 
when the two CAIs examined were added to latanoprost.
This study included 11 subjects with POAG, three 
with OH, and six with ACG. Although there are clear 
differences in the underlying causes of  hyper-IOP between 
POAG and ACG, the IOP-lowering mechanism and effect 
of topical antiglaucoma agents including CAIs is consid-
ered common among the patients who were included in 
this study. Regardless, to assess whether there were any 
differences of efficacy between brinzolamide and dorzol-
amide among the different patient groups, we performed 
a stratified analysis and found that in 11 POAG patients 
reduction of daytime IOP was –3.5 ± 2.5 mmHg by 
dorzolamide bid, –4.6 ± 2.5 mmHg by dorzolamide tid, 
Table 1 Time-course of intraocular pressure (iOP; mean ± sD) during overnight hospital stay in three treatment groups
IOP, mmHg
Baseline 09:00 12:00 15:00 18:00 21:00 24:00 06:00 09:00
Dorzolamide bid 20.0 ± 1.4 17.3 ± 2.6 15.7 ± 2.6 16.5 ± 1.7 16.6 ± 2.4 15.7 ± 1.6 15.9 ± 2.0 15.9 ± 2.5 15.5 + 1.4
Dorzolamide tid 20.0 ± 1.5 15.5 ± 2.7 15.2 ± 2.0 15.6 ± 2.1 16.6 ± 2.1 15.7 ± 2.3 16.5 ± 2.0 15.8 ± 2.0 15.3 ± 1.4
Brinzolamide bid 20.0 ± 1.4 16.8 ± 2.9 16.2 ± 2.0 16.1 ± 1.9 16.7 ± 2.0 15.9 ± 2.8 16.9 ± 3.3 16.6 ± 3.3 15.8 + 1.4Clinical Ophthalmology 2009:3 398
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and –3.6 ± 2.3 mmHg by brinzolamide bid; in six ACG 
patients the results were –2.8 ± 1.7 mmHg, –3.6 ± 1.4 mmHg, 
and 3.7 ± 1.4 mmHg, respectively. No significant difference 
was noted between POAG and ACG patients on any of the 
test regimens. Moreover, the results of nighttime IOP were 
similar to those obtained during daytime (data not shown). 
Therefore CAI efficacy seems common in various glaucoma 
patients with hyper-IOP.
Several previous studies have reported that dorzolamide 
(1% and 2%) is associated with burning sensation or irritation 
because of its acidic formulation (pH, 5.6). Brinzolamide, 
on the other hand, often induces blurred vision due to its 
insoluble carboxyvinyl polymer. As was expected, similar 
results were noted in the present study: eight patients reported 
eye irritation while on dorzolamide and 12 patients reported 
blurred vision on brinzolamide. These symptoms were tran-
sient and faded without treatment.
We recorded that nine patients preferred dorzolamide 
and two preferred brinzolamide whereas nine gave a neutral 
answer. Compliance is a key issue in the treatment of  glaucoma; 
patients are thought more likely to adhere to a course of  therapy 
that is well tolerated. In an earlier prospective, multicenter, 
double-blind, parallel group trial24 although blurred vision 
occurred in 20%–25% of subjects who took brinzolamide, 
this medication was assessed as significantly more comfort-
able than dorzolamide 2%. In that study, the concentration of 
dorzolamide was twice as high as the 1% solution examined 
in this study. Other researchers have reported that substituting 
brinzolamide 1% for dorzolamide 1% in Japanese patients 
with POAG maintained stable IOP while improving ocular 
comfort without significant increase of blurred vision.22,23
In the domestic phase IIb study of dorzolamide,25 no 
significant difference of efficacy was observed between 
1% and 2% solutions whereas the latter concentration 
was associated with more adverse reactions. These results 
influenced the Japanese regulatory authority to approve 
dorzolamide 0.5% and 1% for clinical use. In the present 
study we observed that patients who received dorzolamide 
1% experienced little ocular discomfort and significantly 
preferred dorzolamide 1% over brinzolamide 1%.
In conclusion, administration of CAIs concomitantly 
with latanoprost elicited significant further reductions 
of 24-hour IOP. The IOP-lowering efficacy was almost 
identical regardless of whether patients received dorzolamide 
Table 2 Reduction of 24-hour and daytime/nighttime intraocular 
pressure (mean ± sD) in three treatment groups
Dorzolamide 
bid
Dorzolamide 
tid
Brinzolamide 
bid
Baseline, mmhg 20.0 ± 1.4 20.0 ± 1.5 20.0 ± 1.4
Week 12, mmhg
  24 hour 16.1 ± 1.6 15.8 ± 1.6 16.4 ± 1.9
  Daytime 16.5 ± 1.9 15.8 ± 1.8 16.4 ± 1.8
  Nighttime 15.8 ± 1.8 15.8 ± 1.6 16.4 ± 2.4
Notes: Daytime, 09:00–18:00; nighttime, 21:00–09:00.
mmHg
Baseline 09:00 15:00 21:00 03:00 09:00
30
25
20
15
10
Mean ± SD
Applying CAI eye drops
P < 0.001
Dorzolamide
Brinzolamide
Dorzolamide
(only 2nd day)
Dorzolamide
Brinzolamide
Figure 1 Twenty-four-hour change of intraocular pressure (iOP) in the three treatment groups.
Notes: , Dorzolamide bid (n = 20); °
, brinzolamide bid (n = 20); •, dorzolamide tid (n = 17). Significant reduction of IOP from baseline was noted in all 3 treatment groups 
at all measurement time-points (paired t-test).Clinical Ophthalmology 2009:3 399
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Figure 2 Percent additional intraocular pressure (IOP) reduction during the day and at night. No significant difference of daytime and nighttime mean percent additional IOP 
reduction was noted among the three treatment groups as determined by analysis of variance.
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Figure 3 Ocular discomfort and adverse events and their duration under treatment with each carbonic anhydrase inhibitor.
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1% bid or tid or brinzolamide 1% bid in combination with 
latanoprost. However, dorzolamide 1% was significantly 
preferred over brinzolamide 1% in our cohort of Japanese 
patients with glaucoma.
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